N Irwin, IA Montgomery, FPM O'Harte, P Frizelle and PR Flatt OBJECTIVE: Compromise of gastric inhibitory polypeptide (GIP) receptor action and activation of cholecystokinin (CCK) receptors represent mechanistically different approaches to the possible treatment of obesity-related diabetes. In the present study, we have compared the individual and combined effects of (Pro 3 )GIP [mPEG] and (pGlu-Gln)-CCK-8 as an enzymatically stable GIP receptor antagonist and CCK receptor agonist molecule, respectively. RESULTS: Twice-daily injections of (pGlu-Gln)-CCK-8 alone and in combination with (Pro 3 )GIP[mPEG] in high-fat-fed mice for 34 days significantly decreased the energy intake throughout the entire study (Po0.05 to Po0.01). Body weights were significantly depressed (Po0.05 to Po0.01) in all treatment groups from day 18 onwards. Administration of (pGlu-Gln)-CCK-8, (Pro 3 )GIP [mPEG] or a combination of both peptides significantly (Po0.01 to Po0.001) decreased the overall glycaemic excursion in response to both oral and intraperitoneal glucose challenge when compared with the controls. Furthermore, oral glucose tolerance returned to lean control levels in all treatment groups. The beneficial effects on glucose homeostasis were not associated with altered insulin levels in any of the treatment groups. In keeping with this, the estimated insulin sensitivity was restored to control levels by twice-daily treatment with (pGlu-Gln)-CCK-8, (Pro 3 )GIP [mPEG] or a combination of both peptides. The blood lipid profile on day 34 was not significantly different between the high-fat controls and all treated mice. CONCLUSION: These studies highlight the potential of (pGlu-Gln)-CCK-8 and (Pro 3 )GIP [mPEG] in the treatment of obesity-related diabetes, but there was no evidence of a synergistic effect of the combined treatment.
INTRODUCTION
Gastric inhibitory polypeptide (GIP) is a gut-derived hormone secreted from the enteroendocrine K-cells of the duodenum. 1 The most widely recognised physiological function of GIP is as an insulin-releasing hormone of the enteroinsular axis and the subsequent regulation of postprandial glucose homeostasis. 2 Thus, the sustained activation of GIP receptors and the stimulation of insulin secretion may have therapeutic value in type 2 diabetes. 1 However, recent data now indicate that GIP exerts direct effects on adipose tissue and lipid metabolism. 3 Thus, functional GIP receptors are present on adipose tissue, 4 the activation of which results in increased lipoprotein lipase activity and expression. 5 In addition, it is well known that fat ingestion is a major stimulus to GIP release and that the consumption of energyrich high-fat diet leads to obesity plus harmful lipid deposition in liver, muscle and islet cells, giving rise to mounting insulin resistance. This scenario promotes glucose intolerance and ultimately culminates in obesity-related diabetes. The blockade of GIP receptor action under such pathophysiological circumstances enhances insulin sensitivity through the mobilisation of tissue triglycerides, depression of hyperinsulinemia and further upregulation of insulin receptors. 3, 6 In keeping with this, the genetic knockout of the GIP receptor protects from obesity-related diabetes. 7 In addition, active immunisation against GIP improves the metabolic control in animals with genetically induced obesityrelated diabetes. 3 Furthermore, subchronic daily administration of the specific and stable GIP receptor antagonist, (Pro 3 GIP), 8 can prevent or reverse many of the established metabolic abnormalities associated with obesity-related diabetes. 3 Notwithstanding this clear potential for the ablation of GIP receptor signalling in the alleviation of obesity-related diabetes, there is no evidence of reduced energy intake in animals with either genetic or chemical GIP receptor knockout. 3, 7 Earlier studies have confirmed that GIP is devoid of effects on feeding behaviour, 9 although more work indicates that genetic deletion of the GIP receptors may reduce cumulative food intake in ovariectomised mice. 10 There is evidence of increased locomotor activity in mice with the knockout of GIP receptors, 11 but in disparity similar observations are made in transgenic mice overexpressing GIP. 12 Thus, it seems unlikely that direct locomotor effects underlie the weight loss observed in mice with ablated GIP signalling. In addition, there are conflicting reports on the effects of compromised GIP receptor signalling on energy expenditure. 13, 14 Thus, a realistic approach to further augment the beneficial effects of GIP receptor antagonism would be through simultaneous reduction of energy intake.
In this context, we have previously attempted to reproduce just such a scenario in high-fat-fed mice by the cojoint administration of the specific and stable GIP receptor antagonist, (Pro 3 )GIP, and the peptide YY . 15 However, we were unable to observe a satiety effect of the peptide YY . 15 Manipulating the endogenous cannabinoid system to suppress the appetite by the administration of the receptor antagonist AM251 (N-(piperidin-1-yl) -5-(4-iodophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide) decreased food intake in obese diabetic (ob/ob) mice and high-fat-fed mice. 16, 17 However, we were unable to demonstrate a synergistic effect of (Pro 3 )GIP treatment in combination with the manipulation of central cannabinoid receptors using AM251. 16 Furthermore, the clinical applicability of cannabinoid receptor blockade has come under severe scrutiny of late owing to the occurrence of adverse events related to depression and anxiety. 18 Thus, another avenue for the restriction of energy intake in combination with GIP receptor blockade is required.
Cholecystokinin (CCK) is a gut peptide secreted by endocrine I-cells in response to nutrient ingestion. 19 The most widely accepted physiological role of CCK is in the short-term regulation of energy balance by potent stimulation of satiety. 20 CCK exists in multiple molecular forms ranging from 58 to 39, 33, 22, 8 and 4 amino acids in length, 21 but the carboxy-terminal octapeptide, CCK-8, is well conserved among species and retains the full range of biological actions. 22 However, CCK is rapidly degraded in the circulation following secretion, resulting in a short biological half-life. 23 However, we have developed (pGlu-Gln)-CCK-8 as an enzymatically stable longer-acting CCK-8 analogue with prominent satiety and metabolic actions. 24 The present study was designed to evaluate the relative efficacy and combined therapeutic utility of two promising new compounds for the treatment of obesity-related diabetes. We have used twice-daily injection of (pGlu-Gln)-CCK-8 or (Pro 3 GIP)GIP[m-PEG], a novel long-acting PEGylated GIP receptor antagonist, 25 alone and in combination in high-fat-fed mice. The effects of chronic treatment on body weight, food intake, oral and intraperitoneal (i.p.) glucose tolerance, estimated insulin sensitivity and circulating blood lipid profile were examined. Food intake and body weight were recorded (10:00 h) every 3-4 days. Intraperitoneal glucose tolerance (18 mmol per kg body weight), oral glucose tolerance (18 mmol per kg body weight) and insulin sensitivity (20 U per kg body weight) tests were performed at the end of the treatment period in the same mice. All acute tests commenced at 10:00 h. Blood lipid profile was also assessed on day 34 in nonfasted mice. Where appropriate, age-matched and lean control NIH male mice maintained on standard rodent maintenance (10% fat, 30% protein and 60% carbohydrate, Trouw Nutrition, Cheshire, UK) were used for comparative purposes. All animal experiments were carried out in accordance with the UK Animals (Scientific Procedures) Act 1986, the Principles of Laboratory Animal Care (NIH publication No. 86-23, revised 1985) and approved by the University of Ulster Animal Ethics Review Committee. All animals were housed individually in an air-conditioned room at 22 ± 2 1C with a 12-h light:12-h dark cycle (lights off between 09:30 and 21:30 h). Treatments and tests were performed during the dark cycle using minimal lighting requirements (low wattage lamps) to safely and efficiently complete the experiments.
MATERIALS AND METHODS

Peptides synthesis
Biochemical analysis
All blood samples (125 ml) were taken from the cut tip of the tail vein of conscious mice at the times indicated in the figures and immediately centrifuged using a Beckman microcentrifuge (Beckman Instruments, Galway, Ireland, UK) for 30 s at 13 000 g. The resulting plasma was then aliquoted into fresh Eppendorf tubes and stored at À 20 1C before analysis. Plasma glucose was assayed by an automated glucose oxidase procedure using a Beckman Glucose Analyser II (Beckman Instruments). Plasma insulin was assayed using a modified dextran-coated charcoal radioimmunoassay. 27 Plasma lipid profile was measured by using a Hitachi Automated Analyser 912 (Boehringer, Mannheim, Germany).
Statistical analysis
Results are expressed as mean ± s.e.m. Data were compared using analysis of variance, followed by a Student-Newman-Keuls post hoc test. Area under the curve (AUC) analyses were calculated using the trapezoidal rule with baseline subtraction. Area above the curveanalyses were calculated in a similarmanner, using the uppermost point as the baseline. Po0.05 was considered to be statistically significant.
RESULTS
Effects of (pGlu-Gln)-CCK-8, (Pro3)GIP[mPEG] and combined peptide administration on food intake and body weight Twice-daily administration of (pGlu-Gln)-CCK-8 alone resulted in significant (Po0.05 to Po0.01) reductions in body weight from day 12 onwards when compared with controls ( Figure 1a) . In addition, mice treated with (Pro 3 )GIP[mPEG] alone and in combination with (pGlu-Gln)-CCK-8 had significantly (Po0.05) decreased body weight compared with controls from day 18 onwards (Figure 1a) . Body weight reductions in mice treated with (Pro 3 )GIP [mPEG] were not associated with alterations in food intake (Figure 1b) . In contrast, all mice administered with (pGlu-Gln)-CCK-8 had significantly (Po0.05 to Po0.01) reduced food intake at numerous observation points throughout the study (Figure 1b (Figure 2a) . The corresponding 0-60-min AUC data revealed that all treatment groups had a significantly (Po0.01 to Po0.001) decreased overall glycaemic excursion compared with high-fat controls. Glucoseinduced plasma insulin concentrations were not significantly different in terms of postinjection and AUC values between all treatment groups and high-fat controls (Figures 2c and d) .
Following an oral glucose load, the plasma glucose levels were significantly (Po0.001) decreased in mice treated with (pGlu-Gln)-CCK-8, (Pro 3 )GIP[mPEG] or a combination of both peptides 30 min post injection compared with high-fat controls (Figure 3a) . This was corroborated from 0-60-min AUC data, where all treatment groups had a significantly (Po0.01 to Po0.001) decreased overall glycaemic excursion compared with high-fat controls and a similar excursion compared with lean control mice (Figure 3b) . Oral glucose-induced plasma insulin concentrations were not significantly different in terms of postinjection and 0-60-min AUC values between all treatment groups and high-fat control mice (Figures 3c and d) .
Effects of (pGlu-Gln)-CCK-8, (Pro3)GIP[mPEG] and combined peptide administration on estimated insulin sensitivity Twice-daily administration of (pGlu-Gln)-CCK-8, (Pro 3 )GIP[mPEG] or a combination of both peptides was associated with an augmented hypoglycaemic effect of exogenous insulin (Figure 4) . Thus, postinjection values and the overall glucose values were significantly (Po0.01 to Po0.001) improved in all treatment groups compared with high-fat controls (Figure 4) . Furthermore, glucose levels in all treatment groups were similar to the levels in lean control mice (Figure 4 
DISCUSSION
In the present study, we evaluated the therapeutic efficacy of twice-daily administration of (pGlu-Gln)-CCK-8, (Pro 3 )GIP[mPEG] or a combination of both peptides in mice with established dietaryinduced obesity-related diabetes. As expected, (pGlu-Gln)-CCK-8 administration alone or in combination with (Pro 3 )GIP [mPEG] resulted in decreased energy intake during the 34-day period, without the induction of desensitisation. In addition to this, lipid infusion was recently shown to rapidly decrease circulating CCK levels as a result of a negative feedback phenomenon. 28 Thus, exogenous (pGlu-Gln)-CCK-8 administration should counter this effect, which could also contribute to the clear beneficial effects observed in the current study. Consistent with this, all mice treated with (pGlu-Gln)-CCK-8 had significantly lowered body weights by the end of the study. (Pro 3 )GIP[mPEG] therapy alone had no effect on energy intake in accordance with the view that GIP lacks effects on feeding behaviour. 9 However, it should be noted that GIP can reduce food intake under conditions of oestrogen depletion. 10 However, (Pro 3 )GIP[mPEG] mice displayed similar reductions in body weight as (pGlu-Gln)-CCK-8-treated mice, despite normal food intake. This highlights the important role of CCK in the regulation of feeding and body-weight control and also the proposed role of GIP as a link between over-nutrition and development of obesity-related diabetes. 3, 29 Although the beneficial effects of (pGlu-Gln)-CCK-8 on body weight can easily be explained through decreased energy intake, the actions of (Pro 3 )GIP[mPEG] are somewhat less discernible. However, GIP is known to activate lipoprotein lipase activity, 5 which would promote plasma triglyceride clearance into adipocytes following feeding. 30 Thus, the direct opposing effect of GIP receptor blockade by circulating (Pro 3 )GIP[mPEG] would encourage the uptake and oxidation of lipids by muscle and liver tissues that lack GIP receptors, 31 promoting weight loss under situations such as high-fat feeding. Interestingly, combined peptide administration did not evoke a greater weight loss than the administration of either compound alone. Indeed, the bodyweight-lowering effects of (pGlu-Gln)-CCK-8 alone appeared to be marginally superior than in the combined peptide group. The explanation for this remains elusive, but it might reflect the plasticity of signalling pathways involved in energy intake and weight regulation. 24 In addition, lipid profile assessment on day 34 revealed no significant difference between all treatment groups and the high-fat controls in terms of circulating triglyceride and cholesterol concentrations. Thus, the lack of a synergistic effect on body weight reduction is not easily explainable, but could be due to issues related to peptide dose and circulating levels, experimental timings, activation of counterregulatory mechanisms related to energy modulation or other confounding factors. However, as suggested previously, 15 it may be that a critical level of food intake and circulating lipids is essential to observe the beneficial effects of GIP receptor antagonism. Nevertheless, further studies are needed to fully delineate the role of GIP receptor blockade under situations of diminished energy intake.
Twice-daily administration of (pGlu-Gln)-CCK-8, (Pro )GIP[mPEG] and (pGlu-Gln)-CCK-8 treatment were not superior to either treatment alone. Therefore, although both compounds have differing modes of action, they possess similar but nonadditive, beneficial effects on glucose homeostasis. Glycaemic control in response to oral glucose challenge was similar to lean controls in all treatment groups, possibly negating any possibility of synergistic effects. The benefits on glucose homeostasis were not associated with altered insulin responses in any of the treatment groups. Thus, although GIP is an important insulinreleasing peptide of the enteroinsular axis, 1 prolonged receptor blockade did not disrupt glucoregulatory mechanisms. This observation is in agreement with previous studies that have used prolonged GIP receptor ablation. 3, 15 In addition, although CCK has well-characterised insulin-releasing actions in humans in response to a mixed meal, 32 its insulinotropic effect is modest in response to a nutrient challenge that consists solely of glucose. 29 In agreement with improved glucose tolerance despite unaltered insulin levels, treatment with (pGlu-Gln)-CCK-8, )GIP[mPEG] or a combination of both peptides was associated with lower glucose concentrations during insulin sensitivity tests. The lack of an additive treatment effect in this instance is likely due to the induction of fundamental counterregulatory mechanisms in the face of impending hypoglycaemia, as glucose levels decreased to o4 mmol l after insulin injection. Furthermore, the estimated insulin sensitivity in all treatment groups was restored to identical levels as observed in lean control animals. Similar observations have been noted previously with prolonged ablation of GIP receptor signalling in both obese diabetic (ob/ob) and high-fat-fed mice. 3 In addition, evidence suggests that CCK is an important regulator of insulin sensitivity during high-fat feeding. 33 This would also imply that the observed beneficial effects on glucose homeostasis with each treatment regimen are a direct result of decreased adiposity and subsequent enhanced insulin action. 34 Indeed, given the similarities in terms of body weight reduction, this seems to be a plausible explanation.
In conclusion, the present study indicates that twice-daily injection of (pGlu-Gln)-CCK-8 or (Pro 3 )GIP[mPEG] is an effective means of improving the metabolic control in high-fat-fed mice. This is consistent with the view that both compounds represent interesting and exciting new approaches for the treatment of obesity-related diabetes. The lack of an additive effect of (pGluGln)-CCK-8 and (Pro 3 )GIP[mPEG] warrants further study, but suggests that the combined activation of CCK receptors and inhibition of GIP receptor action has no extra advantage in the treatment of obesity-related diabetes.
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